Financing channel feed – Endpoints News

Financing channel feed

Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart

8 years ago

Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as PhII cancer trial looms

8 years ago

Langer-backed Kala scores $90M IPO as it lines up a pair of NDAs

8 years ago

What's holding back biotech M&A? SVB tracks a trend and calls a comeback

8 years ago

With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round

8 years ago

Clarus readies a slate of big PhIII risk-sharing bets with a new $910M fund

8 years ago

Akcea IPO stumbles and falls well below the range, but still raises $175M

8 years ago

Ocular Therapeutix's last-minute gambit fails to salvage its second FDA application, shares plunge

8 years ago

Big Pharma VCs jump in to back a $63M mission to tackle a genetic driver of Alzheimer’s

8 years ago

After raising $100M, Google-backed Evelo looks to blaze a new trail with monoclonal microbials

8 years ago

Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII

8 years ago

Google’s data-crunching mavens at GV buy in to Decibel’s R&D program for hearing loss, tinnitus

8 years ago

Medicxi’s new fund jumps off the beaten biotech path to lead a $30M round for diabetes program

8 years ago

Fast-moving Sienna Bio vaults from buyout to B round to $75M IPO

8 years ago

Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul

8 years ago

Atlas Venture vows to keep doing well by doing good with its new, $350M biotech fund

8 years ago

Mersana scores a $75M IPO as Wall Street continues to embrace biotech

8 years ago

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

8 years ago

Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality

8 years ago

Langer-backed Sigilon sets sail with $23M and new ‘living’ cell therapy tech

8 years ago

Rubius lands $120M bonanza to fund a groundbreaking pipeline effort on a new drug platform

8 years ago

Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

8 years ago

Biotech crossover investor Foresite is lining up a $650M stake for the big gambles to come

8 years ago

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

8 years ago

First page Previous page 138 139 140141142 143 144 Next page Last page